Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

China Pharma places 2.5 million shares and raises $5 million gross

China Pharma completed a registered direct placement of 2,500,000 common shares at $2.00 each, generating gross proceeds of $5 million before fees. The net proceeds are intended for working capital and general corporate purposes. FT Global Capital acted as exclusive placement agent; the transaction was carried out under an S-3 shelf registration. » More on de.investing.com
China Pharma falls nearly 70% after $5 million direct placement

China Pharma's stock fell about 69% on Wednesday after announcing a registered direct placement of 2.5 million common shares at $2 per share. The gross proceeds are $5 million; net proceeds are intended for working capital and general corporate purposes. The transaction is expected to close around July 23, 2026, and FT Global Capital is acting as exclusive placement agent. » More on de.investing.com
China Pharma Holdings sees no internal explanation for unusual trading activity

China Pharma Holdings told the NYSE American on inquiry that the company is not aware of any material, non-public information that could explain the unusual trading activity in its common stock. The share rose by almost 90% to $1.00 in the prior week; according to data from InvestingPro the stock generally shows high volatility and appears overvalued at the current level. The company gave no further details on the nature of the unusual market movement. » More on de.investing.com
China Pharma Holdings approves reverse split up to 1:20 and elects three independent directors

At the annual general meeting, shareholders of China Pharma Holdings voted to implement a reverse split at a ratio of up to 1:20, with the timing and execution at the board’s discretion. Gene Michael Bennett, Yingwen Zhang and Baowen Dong were elected as independent directors. Also approved was the third amendment to the amended and restated Long-Term Incentive Plan of 2010. » More on de.investing.com

Financials

In the last quarter, China Pharma had revenue of €830.94K and net profit of -€1.28M

(EUR)	June 2026	YoY
Revenue	830.94K	4.52%
Gross profit	73.22K	199.19%
Net profit	-1.28M	185.01%
EBITDA	-253.17K	65.65%

Fundamentals

Metric	Value
Market capitalization	€22.13M
Number of shares	43.02M
52-week high/low	€17.32 - €0.34
Dividends	No
Beta	0.96
P/E ratio	-0.56
PEG ratio	0.02
P/B ratio	0.07
P/S ratio	6.26

Company profile

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.